Carolyn Ng, Ph.D.Dr. Carolyn Ng is Managing Director of Vertex Ventures HC and serves on the board of directors of Obsidian. At Vertex HC, Dr. Ng is responsible for driving venture investments across biotechnology, medical devices and health technology fields. She currently serves on the board of directors for Twentyeight-Seven Therapeutics, Bicycle Therapeutics (NASDAQ: BCYC), Nuvaira, and Boundless Bio. She was also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for USD430M) and Earlens. Prior to joining Vertex, Dr. Ng was a Pharma Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm. Dr. Ng holds a Ph.D. in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship.
< Back to Board